- Bio-marker company Oxford BioDynamics booked an annual loss as it increased spending on R&D and staff while revenue remained flat.

Pre-tax losses for the year through September amounted to £2.4m, compared to losses of £4.0m on-year, when the company incurred one-off IPO costs.

Revenue was roughly flat at around £1.2m.

'In 2018 we have continued to build on the strong foundations established in 2017 following our successful IPO,' chief executive Christian Hoyer Millar said.

'Investment in our commercial infrastructure has allowed us to further our customer and geographical reach, with our EpiSwitch technology increasingly becoming the leading industry standard for identifying epigenetic biomarkers.'

'Our EpiSwitch platform is fast becoming internationally recognised as an effective and novel platform to improve therapeutic options.'

Story provided by